JP2018522847A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522847A5
JP2018522847A5 JP2017564846A JP2017564846A JP2018522847A5 JP 2018522847 A5 JP2018522847 A5 JP 2018522847A5 JP 2017564846 A JP2017564846 A JP 2017564846A JP 2017564846 A JP2017564846 A JP 2017564846A JP 2018522847 A5 JP2018522847 A5 JP 2018522847A5
Authority
JP
Japan
Prior art keywords
tetrahydro
pyridin
oxo
phenylamino
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017564846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522847A (ja
Filing date
Publication date
Priority claimed from PCT/EP2015/063527 external-priority patent/WO2015193339A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/063540 external-priority patent/WO2016202755A1/en
Publication of JP2018522847A publication Critical patent/JP2018522847A/ja
Publication of JP2018522847A5 publication Critical patent/JP2018522847A5/ja
Withdrawn legal-status Critical Current

Links

JP2017564846A 2015-06-17 2016-06-14 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類 Withdrawn JP2018522847A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15172613.0 2015-06-17
EP15172613 2015-06-17
EPPCT/EP2015/063527 2015-06-17
PCT/EP2015/063527 WO2015193339A1 (en) 2014-06-17 2015-06-17 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
EP15177393.4 2015-07-17
EP15177393 2015-07-17
PCT/EP2016/063540 WO2016202755A1 (en) 2015-06-17 2016-06-14 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones

Publications (2)

Publication Number Publication Date
JP2018522847A JP2018522847A (ja) 2018-08-16
JP2018522847A5 true JP2018522847A5 (enExample) 2019-04-04

Family

ID=57545595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564846A Withdrawn JP2018522847A (ja) 2015-06-17 2016-06-14 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類

Country Status (8)

Country Link
US (1) US10227299B2 (enExample)
EP (1) EP3310775B1 (enExample)
JP (1) JP2018522847A (enExample)
CN (1) CN107922389A (enExample)
CA (1) CA2989469A1 (enExample)
TW (1) TW201718534A (enExample)
UY (1) UY36737A (enExample)
WO (1) WO2016202755A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157914B1 (en) 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
TN2017000329A1 (en) 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
KR20230094197A (ko) 2020-09-23 2023-06-27 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
KR20230107419A (ko) 2020-10-09 2023-07-14 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료 방법
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024159094A1 (en) * 2023-01-27 2024-08-02 Enliven Inc. Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
ES2620316T3 (es) 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
HK1218750A1 (zh) 2013-03-21 2017-03-10 Bayer Pharma Aktiengesellschaft 3-杂芳基取代的吲唑
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
HK1222846A1 (zh) 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 取代的苄基吡唑
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
HK1223097A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3157914B1 (en) 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
TN2017000329A1 (en) 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US10308629B2 (en) * 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
US20200216439A1 (en) 2015-12-16 2020-07-09 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones

Similar Documents

Publication Publication Date Title
JP2018522847A5 (enExample)
JP2021515033A5 (enExample)
KR102534028B1 (ko) 트리아졸로피리미딘 화합물 및 그의 용도
JP2017530185A5 (enExample)
JP2020506946A5 (enExample)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2016517878A5 (enExample)
HRP20130106T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2023525762A5 (enExample)
JP2016523911A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2348628C2 (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
HRP20141093T1 (hr) Triazolopirimidini
JP2019505541A5 (enExample)
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2016503009A5 (enExample)
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
JP2017537948A5 (enExample)
RU2005108999A (ru) Азотсодержащие ароматические производные
RU2014147243A (ru) Производные пирролопиридинона в качестве ttx-s блокаторов
JP2022548568A5 (enExample)
RU2016141645A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина